Our results suggest that the therapeutic effect of SLBZP on NAFLD is related to the regulation of hepatic mitochondrial energy metabolism by intestinal flora and its metabolites and is possibly associated with the UCP2/AMPK/IF1 signalling pathway. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.